Indeed, a markedly increased SIRT7 expression was observed when EGF signaling activity was blocked in MDA-231 breast cancer cells by erlotinib, whereas EGF stimulation accelerated SIRT7 protein turnover (Fig. 7a, b). Here, SIRT7 is linked to breast carcinoma.